The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis

被引:4
|
作者
Li, Xiaoyan [1 ]
He, Jie [2 ,3 ]
Sun, Qiuhua [1 ]
机构
[1] Zhejiang Chinese Med Univ, Sch Nursing, 548 Binwen Rd, Hangzhou 310000, Zhejiang, Peoples R China
[2] Chengdu Med Coll, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Chengdu 610500, Sichuan, Peoples R China
[3] Chengdu Med Coll, Clin Med Coll, Chengdu 610500, Sichuan, Peoples R China
关键词
Sarcopenia; Metabolic dysfunction-associated steatotic; liver disease (MASLD); Prevalence; Systematic review; Meta-analysis; INSULIN-RESISTANCE; FIBROSIS; NAFLD; RISK; STEATOHEPATITIS; QUALITY;
D O I
10.1016/j.clnu.2024.07.006
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background and aims: Sarcopenia is a common complication in patients with metabolic dysfunctionassociated steatotic liver disease (MASLD). However, the prevalence and its impact on the survival of sarcopenia in patients with MASLD is unknown. In this study, we aimed to assess the prevalence and effects of sarcopenia in patients with MASLD. Methods: Systematic review and meta-analysis of full texts of relevant studies were searched from inception until June 12, 2024 in five databases (PubMed, Cochrane Library, Embase, Web of Science, and the China National Knowledge Infrastructure). Next, we assessed the prevalence of sarcopenia in MASLD, and calculated the ORs and HRs between sarcopenia and MASLD based on the adjusted data from individual studies. Statistical analyses were performed using Stata 11.0. Results: Of the 2984 records considered, 29 studies recruiting 63,330 patients were included. The pooled prevalence of sarcopenia in patients with MASLD was 23.5% overall (95% CI; 19.1%-27.9%, I2 = 99.6%), and was higher in Asian patients, male, cross-sectional studies, when BIA were employed to measure muscle mass, one criterion of diagnosis sarcopenia, MASLD was diagnosed employing MRI, and moderate-quality studies. Sarcopenia was associated with MASLD patients (adjusted odds ratio [aOR] 2.08, 95% CI 1.58 -2.74, I2 = 93.6%) with similar findings in subgroups stratified by age, study design, methods for measuring muscle mass, assessment method to detect sarcopenia, and study quality. The association between all-cause mortality further supports the association between sarcopenia and poor prognosis with MASLD (aHR 1.59, 95% CI 1.33-1.91, I2 = 0%). Conclusions: Sarcopenia was strongly associated with MASLD progression and was a risk factor not only for MASLD pathogenesis but was also markedly correlated with MASLD-associated mortality. (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:2005 / 2016
页数:12
相关论文
共 50 条
  • [31] Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
    Sanyal, Arun J.
    Husain, Mansoor
    Diab, Crystel
    Mangla, Kamal Kant
    Shoeb, Ahsan
    Lingvay, Ildiko
    Tapper, Elliot B.
    AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE, 2024, 41
  • [32] Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
    Iturbe-Rey, Santiago
    Maccali, Claudia
    Arrese, Marco
    Aspichueta, Patricia
    Oliveira, Claudia P.
    Castro, Rui E.
    Lapitz, Ainhoa
    Izquierdo-Sanchez, Laura
    Bujanda, Luis
    Perugorria, Maria J.
    Banales, Jesus M.
    Rodrigues, Pedro M.
    ATHEROSCLEROSIS, 2025, 400
  • [33] Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine MASLD
    Stefan, Norbert
    Targher, Giovanni
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2025, : 226 - 227
  • [34] Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
    Kasprzak-Drozd, Kamila
    Nizinski, Przemyslaw
    Kasprzak, Paulina
    Kondracka, Adrianna
    Oniszczuk, Tomasz
    Rusinek, Agata
    Oniszczuk, Anna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [35] Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
    Suvarna, Renuka
    Shetty, Sahana
    Pappachan, Joseph M.
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [36] THE EFFECTS OF TESTOSTERONE REPLACEMENT THERAPY IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): A SYSTEMATIC REVIEW
    Mahmoud, Maya
    Kawtharany, Hassan
    Awali, Mohamed
    Mahmoud, Nadine
    Mohamed, Islam
    Alsakarneh, Saqr
    Syn, Wing-Kin
    GASTROENTEROLOGY, 2024, 166 (05) : S1656 - S1656
  • [37] Evaluating the Impact of Melatonin Administration in Patients With Metabolic-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis
    Singh, Avneet
    Garcia, Alexander
    Hasan, Fariha
    Laique, Fatima
    Haris, Muhammad
    Mohiuddin, Mubashir
    Abidi, Zehara
    Jover, Queenzy
    Bassi, Mehak
    Dalal, Kunal
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1248 - S1249
  • [38] Growth hormone augmentation in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials
    Mohamed, Islam
    Gautam, Misha
    Abosheaishaa, Hazem
    Hussain, Sophia
    Kumar, Kopal
    Kotak, Anaya
    Baugh, Macy
    Qureshi, Raabia
    Jaber, Fouad
    Dahiya, Dushyant Singh
    Alba, Laura
    Duong, Nikki
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 36 (11) : 1259 - 1266
  • [39] Metabolic dysfunction-associated steatotic liver disease and the risk of mortality in individuals with type 2 diabetes: a systematic review and meta-analysis
    Wongtrakul, Wasit
    Charatcharoenwitthaya, Natthinee
    Charatcharoenwitthaya, Phunchai
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 36 (04) : 351 - 358
  • [40] A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis. '
    Li, Chao
    Wang, Ting
    Song, Jinbo
    CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (07)